Cancer research has seen remarkable advances in recent years. As we approach 2026, a particularly promising discovery has emerged- one that could help the immune system recognize and attack cancer cells more effectively.
Let’s break down what scientists at MIT and Stanford have uncovered.
The Research from MIT- In a Gist
In a recent study published in Nature Biotechnology, researchers from MIT and Stanford unveiled a novel strategy to boost cancer immunotherapy. Their goal was to help the immune system better distinguish cancer cells from healthy cells—one of the biggest challenges in cancer treatment.
The team focused on a hidden “off switch” used by cancer cells: a dense sugar coating on their surface that suppresses immune activity and allows tumors to escape detection. By targeting this sugar shield, the researchers were able to lift an immune brake that normally prevents immune cells from attacking tumors.
Although still in early stages, this approach could significantly enhance the effectiveness of existing antibody-based therapies.
How Cancer Uses Immune “Brakes”
Cancer cells are experts at avoiding immune surveillance. One well-known strategy involves the PD-1/PD-L1 checkpoint pathway, which many immunotherapy drugs already target. Blocking this interaction removes a molecular brake, allowing T cells to attack tumors.
However, checkpoint inhibitors don’t work for everyone, prompting scientists to search for additional immune-suppressive pathways.
A Sugar-Based Immune Checkpoint
Beyond protein checkpoints, cancer cells also exploit glycans– complex sugar structures found on the cell surface. While glycans are present on all cells, cancer cells often display abnormal, sialic-acid–rich glycans.
These sialic acids interact with immune cell receptors called Siglecs, triggering signals that suppress immune activation- much like the PD-1/PD-L1 pathway.
AbLecs: Combining Antibodies and Lectins
Blocking these sugar-based interactions has been challenging because lectins (proteins that bind sugars) usually bind too weakly to be effective on their own.
To overcome this, the researchers created AbLecs– multifunctional molecules that combine:
- an antibody that targets tumor cells, and
- a lectin that binds sialic acids on cancer cell glycans.
In this study, the antibody used was trastuzumab, a clinically approved drug targeting HER2. One arm of the antibody was replaced with a lectin domain (Siglec-7 or Siglec-9-based), allowing precise delivery to tumor cells and effective blockade of the sugar-based immune brake.
Promising Preclinical Results
In cell cultures and mouse models engineered with human immune receptors, AbLecs significantly boosted immune activity. Immune cells such as macrophages and natural killer cells were more effective at attacking and killing cancer cells.
Importantly, the AbLec design is modular. Different antibodies can be swapped in to target different tumor antigens, making the approach adaptable across multiple cancer types.
What’s Next?
The researchers have launched a startup, Valora Therapeutics, to advance AbLecs toward the clinic. Human clinical trials are expected to begin within the next two to three years.
If successful, this strategy could open a new chapter in cancer immunotherapy- one that targets not just proteins, but the sugar signals cancer cells use to hide.
That was informative, thanks for sharing.